Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris
Sponsor: Priovant Therapeutics, Inc.
Summary
This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with lichen planopilaris
Official title: A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults With Lichen Planopilaris
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
342
Start Date
2026-03-19
Completion Date
2029-07-31
Last Updated
2026-07-08
Healthy Volunteers
No
Conditions
Interventions
Oral Brepocitinib
Oral
Placebo
Oral
Locations (61)
Clinical Trial Site
Birmingham, Alabama, United States
Clinical Trial Site
Phoenix, Arizona, United States
Clinical Trial Site
Scottsdale, Arizona, United States
Clinical Trial Site
Irvine, California, United States
Clinical Trial Site
Oakland, California, United States
Clinical Trial Site
Sacramento, California, United States
Clinical Trial Site
San Francisco, California, United States
Clinical Trial Site
Denver, Colorado, United States
Clinical Trial Site
Farmington, Connecticut, United States
Clinical Trial Site
New Haven, Connecticut, United States
Clinical Trial Site
Miami, Florida, United States
Clinical Trial Site
Chicago, Illinois, United States
Clinical Trial Site
Skokie, Illinois, United States
Clinical Trial Site
Clarksville, Indiana, United States
Clinical Trial Site
Indianapolis, Indiana, United States
Clinical Trial Site
Leawood, Kansas, United States
Clinical Trial Site
Louisville, Kentucky, United States
Clinical Trial Site
Boston, Massachusetts, United States
Clinical Trial Site
Burlington, Massachusetts, United States
Clinical Trial Site
Ann Arbor, Michigan, United States
Clinical Trial Site
Ann Arbor, Michigan, United States
Clinical Trial Site
Medina, Minnesota, United States
Clinical Trial Site
Minneapolis, Minnesota, United States
Clinical Trial Site
Kansas City, Missouri, United States
Clinical Trial Site
Lee's Summit, Missouri, United States
Clinical Trial Site
Lebanon, New Hampshire, United States
Clinical Trial Site
New Hyde Park, New York, United States
Clinical Trial Site
New York, New York, United States
Clinical Trial Site
Durham, North Carolina, United States
Clinical Trial Site
Cleveland, Ohio, United States
Clinical Trial Site
Columbus, Ohio, United States
Clinical Trial Site
Medina, Ohio, United States
Clinical Trial Site
Portland, Oregon, United States
Clinical Trial Site
Philadelphia, Pennsylvania, United States
Clinical Trial Site
Charleston, South Carolina, United States
Clinical Trial Site
Murfreesboro, Tennessee, United States
Clinical Trial Site
Smyrna, Tennessee, United States
Clinical Trial Site
Austin, Texas, United States
Clinical Trial Site
Austin, Texas, United States
Clinical Trial Site
Cedar Park, Texas, United States
Clinical Trial Site
Prosper, Texas, United States
Clinical Trial Site
Tyler, Texas, United States
Clinical Trial Site
Murray, Utah, United States
Clinical Trial Site
Norfolk, Virginia, United States
Clinical Trial Site
Richmond, Virginia, United States
Clinical Trial Site
Roanoke, Virginia, United States
Clinical Trial Site
Mill Creek, Washington, United States
Clinical Trial Site
Adelaide, Australia
Clinical Trial Site
Perth, Australia
Clinical Trial Site
Sydney, Australia
Clinical Trial Site
Edmonton, Alberta, Canada
Clinical Trial Site
Guelph, Ontario, Canada
Clinical Trial Site
London, Ontario, Canada
Clinical Trial Site
Toronto, Ontario, Canada
Clinical Trial Site
Toronto, Ontario, Canada
Clinical Trial Site
Salford, Manchester, United Kingdom
Clinical Trial Site
Glasgow, Scotland, United Kingdom
Clinical Trial Site
Brighton, United Kingdom
Clinical Trial Site
London, United Kingdom
Clinical Trial Site
London, United Kingdom
Clinical Trial Site
Wrexham, United Kingdom